Katherine Goodrich - 12 Jun 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role: Director
Signature: /s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol: TARS
Transactions as of: 12 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2025, 16:05:11 UTC
Previous filing: 15 Nov 2024
Next filing: 14 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Goodrich Katherine	Director	C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE	/s/ Scott Sieckert, Attorney-in-Fact	16 Jun 2025	0002044770

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TARS	Stock Option (right to buy)	Award	$0	+4,540		$0.000000	4,540	12 Jun 2025	Common Stock	4,540	$40.95	Direct	F1
transaction	TARS	Restricted Stock Units	Award	$0	+2,954		$0.000000	2,954	12 Jun 2025	Common Stock	2,954		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
F2	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
F3	RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.